These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38932142)

  • 1. Premature Activation of the HIV-1 Protease Is Influenced by Polymorphisms in the Hinge Region.
    Tabler CO; Wegman SJ; Alhusaini N; Lee NF; Tilton JC
    Viruses; 2024 May; 16(6):. PubMed ID: 38932142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.
    Mata-Munguía C; Escoto-Delgadillo M; Torres-Mendoza B; Flores-Soto M; Vázquez-Torres M; Gálvez-Gastelum F; Viniegra-Osorio A; Castillero-Manzano M; Vázquez-Valls E
    BMC Bioinformatics; 2014 Mar; 15():72. PubMed ID: 24629078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
    Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
    J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.
    Su CT; Ling WL; Lua WH; Haw YX; Gan SK
    BMC Bioinformatics; 2016 Dec; 17(Suppl 19):500. PubMed ID: 28155724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.
    Bandaranayake RM; Kolli M; King NM; Nalivaika EA; Heroux A; Kakizawa J; Sugiura W; Schiffer CA
    J Virol; 2010 Oct; 84(19):9995-10003. PubMed ID: 20660190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.
    Santos AF; Tebit DM; Lalonde MS; Abecasis AB; Ratcliff A; Camacho RJ; Diaz RS; Herchenröder O; Soares MA; Arts EJ
    Antimicrob Agents Chemother; 2012 May; 56(5):2719-25. PubMed ID: 22330918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance.
    Masso M; Vaisman II
    BMC Genomics; 2013; 14 Suppl 4(Suppl 4):S3. PubMed ID: 24268064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoscale flow cytometry reveals interpatient variability in HIV protease activity that correlates with viral infectivity and identifies drug-resistant viruses.
    Bonar MM; Tabler CO; Haqqani AA; Lapointe LE; Galiatsos JA; Joussef-Piña S; Quiñones-Mateu ME; Tilton JC
    Sci Rep; 2020 Oct; 10(1):18101. PubMed ID: 33093566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HIV-1 Viral Protease Is Activated during Assembly and Budding Prior to Particle Release.
    Tabler CO; Wegman SJ; Chen J; Shroff H; Alhusaini N; Tilton JC
    J Virol; 2022 May; 96(9):e0219821. PubMed ID: 35438536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hierarchical model of HIV-1 protease drug resistance.
    Goodsell DS
    Appl Bioinformatics; 2002; 1(1):3-12. PubMed ID: 15130852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to protease inhibitors.
    Kuritzkes DR
    J HIV Ther; 2002 Nov; 7(4):87-91. PubMed ID: 12733606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.
    Dumans AT; Barreto CC; Santos AF; Arruda M; Sousa TM; Machado ES; Sabino EC; Brindeiro RM; Tanuri A; Duarte AJ; Soares MA
    Infect Genet Evol; 2009 Jan; 9(1):62-70. PubMed ID: 18992847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design.
    Velazquez-Campoy A; Muzammil S; Ohtaka H; Schön A; Vega S; Freire E
    Curr Drug Targets Infect Disord; 2003 Dec; 3(4):311-28. PubMed ID: 14754432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance within the protease inhibitor class.
    Race E
    Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
    [No Abstract]   [Full Text] [Related]  

  • 16. Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia.
    Huruy K; Maier M; Mulu A; Liebert UG
    J Med Virol; 2015 Jun; 87(6):978-84. PubMed ID: 25649964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland.
    Smoleń-Dzirba J; Rosińska M; Kruszyński P; Bratosiewicz-Wąsik J; Wojtyczka R; Janiec J; Szetela B; Beniowski M; Bociąga-Jasik M; Jabłonowska E; Wąsik TJ; The Cascade Collaboration In EuroCoord A
    Med Sci Monit; 2017 Feb; 23():682-694. PubMed ID: 28167814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.
    Kantor R; Katzenstein D
    AIDS Rev; 2003; 5(1):25-35. PubMed ID: 12875105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
    Lambert-Niclot S; Flandre P; Canestri A; Peytavin G; Blanc C; Agher R; Soulié C; Wirden M; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Feb; 52(2):491-6. PubMed ID: 18039922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease inhibition in African subtypes of HIV-1.
    Velázquez-Campoy A; Vega S; Fleming E; Bacha U; Sayed Y; Dirr HW; Freire E
    AIDS Rev; 2003; 5(3):165-71. PubMed ID: 14598565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.